Evidence map›Paper›PMID 34572961›Full record

ReviewAntioxidants (Basel, Switzerland)2021

Mitochondrial Superoxide Dismutase in Cisplatin-Induced Kidney Injury.

Kranti A Mapuskar, Emily J Steinbach, Amira Zaher, Dennis P Riley, Robert A Beardsley, Jeffery L Keene, Jon T Holmlund, Carryn M Anderson, Diana Zepeda-Orozco, John M Buatti and 2 more

Open access · goldAbstract readReview
In one paragraph

Review in Antioxidants (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
6.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 54 citations in OpenAlex.

  1. ASIV Attenuates Cisplatin-Induced Proximal Tubular Injury by Enhancing Mitochondrial Biogenesis and Mitophagy Through the ADRA1A/AMPK/FOXO3A Pathway.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026
    Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. An AOP-guidedNAM journal · 2026
    Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Renoprotective Effects of Brown-StrainInternational journal of molecular sciences · 2024
    Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Kranti A MapuskarFree Radical and Radiation Biology Program, Department of Radiation Oncology, University of Iowa, Iowa City, IA 52242, USA.ORCID 0000-0002-7311-7184
Emily J SteinbachFree Radical and Radiation Biology Program, Department of Radiation Oncology, University of Iowa, Iowa City, IA 52242, USA.
Amira ZaherBiomedical Science Program, Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA 52242, USA.
Dennis P RileyGalera Therapeutics, Inc., Malvern, PA 19355, USA.
Robert A BeardsleyGalera Therapeutics, Inc., Malvern, PA 19355, USA.ORCID 0000-0002-5129-3910
Jeffery L KeeneGalera Therapeutics, Inc., Malvern, PA 19355, USA.
Jon T HolmlundGalera Therapeutics, Inc., Malvern, PA 19355, USA.
Carryn M AndersonFree Radical and Radiation Biology Program, Department of Radiation Oncology, University of Iowa, Iowa City, IA 52242, USA.
Diana Zepeda-OrozcoCenter for Clinical and Translational Research, The Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH 43205, USA.
John M BuattiFree Radical and Radiation Biology Program, Department of Radiation Oncology, University of Iowa, Iowa City, IA 52242, USA.
Douglas R SpitzFree Radical and Radiation Biology Program, Department of Radiation Oncology, University of Iowa, Iowa City, IA 52242, USA.
Bryan G AllenFree Radical and Radiation Biology Program, Department of Radiation Oncology, University of Iowa, Iowa City, IA 52242, USA.
University of Iowa · USNationwide Children's Hospital · US

Funding

Pulmonary Toxicology Facility CoreP30ES005605 · NIEHS · UNIVERSITY OF IOWA · PI Jong Sung Kim · 1990 to 2026
$40.5M
Project 3: MRI Imaging of Redox Active Fe Predicts GBM Responses to Pharmacological AscorbateP01CA217797 · NCI · UNIVERSITY OF IOWA · PI BUETTNER, GARRY R · 2018 to 2022
$9.6M
NCI NIH HHS P01 CA217797NIEHS NIH HHS P30 ES005605
6 · The paper itself

Abstract

Cisplatin is a chemotherapy agent commonly used to treat a wide variety of cancers. Despite the potential for both severe acute and chronic side effects, it remains a preferred therapeutic option for many malignancies due to its potent anti-tumor activity. Common cisplatin-associated side-effects include acute kidney injury (AKI) and chronic kidney disease (CKD). These renal injuries may cause delays and potentially cessation of cisplatin therapy and have long-term effects on renal function reserve. Thus, developing mechanism-based interventional strategies that minimize cisplatin-associated kidney injury without reducing efficacy would be of great benefit. In addition to its action of cross-linking DNA, cisplatin has been shown to affect mitochondrial metabolism, resulting in mitochondrially derived reactive oxygen species (ROS). Increased ROS formation in renal proximal convoluted tubule cells is associated with cisplatin-induced AKI and CKD. We review the mechanisms by which cisplatin may induce AKI and CKD and discuss the potential of mitochondrial superoxide dismutase mimetics to prevent platinum-associated nephrotoxicity.

Indexed as

acute kidney injurychronic kidney diseasecisplatinmitochondriamitochondrial metabolismreactive oxygen speciessuperoxidesuperoxide dismutase

Identifiers

PMID34572961
PMCPMC8469643
OpenAlexW3194216026

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.